Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that further to United States Food and Drug Administration (USFDA) inspection at the Companys Goa manufacturing facility in September 2019 and the warning letter received in February 2020 the Goa plant recently underwent a USFDA inspection from 16th - 26th August 2022. On conclusion of the inspection the Company has now received 6 observations with some referencing to the observations made during the September 2019 inspection. There are no data integrity (DI) observations. The Company will work closely with the USFDA and is committed to address these within the stipulated time.Kindly take the above information on record.
Ask Value Research 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
